

Pierluigi Russo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9518177/pierluigi-russo-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

924
citations

16
h-index

28
g-index

63
ext. papers

1,090
ext. citations

3.8
avg, IF

3.46
L-index

#	Paper	IF	Citations
60	Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2006 , 253, 287-93	5.5	103
59	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. <i>European Heart Journal</i> , 2015 , 36, 2454-62	9.5	74
58	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 412-9	5	68
57	The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. <i>Journal of Neurology</i> , 2004 , 251, 432-9	5.5	59
56	Risk factors for uncontrolled hypertension in Italy. <i>Journal of Human Hypertension</i> , 2004 , 18, 207-13	2.6	47
55	Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 1086-94	5	41
54	Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. <i>Annals of Oncology</i> , 2010 , 21, 2081-2087	10.3	38
53	How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 965-73	3.8	37
52	Predictors of quality of life among patients with multiple sclerosis: an Italian cross-sectional study. <i>Journal of the Neurological Sciences</i> , 2007 , 252, 121-9	3.2	35
51	MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY. <i>International Journal of Technology Assessment in Health Care</i> , 2015 , 31, 210-3	1.8	28
50	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 578-85	5	26
49	Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 168-72 ⁹	5.9	22
48	Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 975-80	5	21
47	Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. <i>Clinical Drug Investigation</i> , 2004 , 24, 409-20	3.2	21
46	Cocaine toxic effect on endothelium-dependent vasorelaxation: an in vitro study on rabbit aorta. <i>Toxicology Letters</i> , 2001 , 123, 43-50	4.4	20
45	Television viewing and personality structure in children. <i>Personality and Individual Differences</i> , 2002 , 32, 977-990	3.3	19
44	Prescription drug use among older adults in Italy: a country-wide perspective. <i>Journal of the American Medical Directors Association</i> , 2014 , 15, 531.e11-531.e15	5.9	15

43	Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 100, 730-742	6.1	14
42	Developing a paradigm of drug innovation: an evaluation algorithm. <i>Drug Discovery Today</i> , 2006 , 11, 999-1006	18.06	14
41	Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1416-1424	6.7	13
40	The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1013-1019	3.8	13
39	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
38	How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). <i>Cancer Medicine</i> , 2020 , 9, 4160-4165	4.8	11
37	Clinical and economic outcomes of pneumonia in children: a longitudinal observational study in an Italian paediatric hospital. <i>Journal of Evaluation in Clinical Practice</i> , 2002 , 8, 341-8	2.5	11
36	Sex Differences in Hemisphere Preference as Assessed by a Paper-And-Pencil Test. <i>International Journal of Neuroscience</i> , 2000 , 100, 29-37	2	11
35	Toxicological effects of beryllium on platelets and vascular endothelium. <i>Toxicology and Applied Pharmacology</i> , 1997 , 144, 262-7	4.6	10
34	Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis. <i>Pharmacoeconomics</i> , 2001 , 19, 57-68	4.4	10
33	Sex differences in EEG correlates of a self-reported measure of hemisphere preference. <i>International Journal of Neuroscience</i> , 2001 , 106, 109-21	2	9
32	Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections. <i>Digestive Surgery</i> , 2000 , 17, 164-72	2.5	9
31	Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study. <i>Clinical Therapeutics</i> , 2007 , 29, 751-8	3.5	8
30	A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study. <i>Clinical Therapeutics</i> , 1999 , 21, 1788-96	3.5	8
29	Clinical and economic effects of central venous catheters on oncology patient care. <i>Journal of Chemotherapy</i> , 2007 , 19, 309-14	2.3	7
28	Interferon alpha in the treatment of chronic hepatitis C in children: a meta-analysis [correction of metanalysis]. <i>Journal of Viral Hepatitis</i> , 2003 , 10, 210-4	3.4	7
27	Adherence to Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Prescriptions Affects Overall Medication Adherence in Older Persons: Evidence From the Italian Nationwide OsMed Health-DB Database. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, 1712-1718	4.6	7
26	Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. <i>Clinical Therapeutics</i> , 2001 , 23, 276-83; discussion 274-5	3.5	6

25	Interaction between cognitive style and school environment: consequences on self-evaluated anxiety and depression. <i>International Journal of Neuroscience</i> , 2001 , 110, 79-90	2	6
24	A decision-theoretic framework for the application of cost-effectiveness analysis in regulatory processes. <i>Pharmacoeconomics</i> , 2009 , 27, 645-55	4.4	5
23	Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three Italian centres. <i>Journal of Immunoassay and Immunochemistry</i> , 2009 , 30, 40-50	1.8	5
22	Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study. <i>Journal of Evaluation in Clinical Practice</i> , 2004 , 10, 511-8	2.5	5
21	Cost offset of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005 , 5, 193-205	2.2	5
20	Under-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	5
19	Solitary nodular disease and multinodular goiter: a retrospective study on suppressive versus replacement levothyroxine therapy. <i>Endocrine Research</i> , 1999 , 25, 229-38	1.9	4
18	Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). <i>Annals of Hematology</i> , 2021 , 100, 481-485	3	4
17	The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience. <i>Liver International</i> , 2018 , 38, 733-741	7.9	3
16	Effects of sodium selenite on vascular smooth muscle reactivity. <i>Pharmacological Research</i> , 2000 , 41, 195-9	10.2	3
15	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017 , 30, 1253-1265	3	2
14	Neuroprotective effects of low-doses of aspirin. <i>Human Psychopharmacology</i> , 2001 , 16, 193-194	2.3	2
13	Una prima valutazione economica dell'impiego di rofecoxib versus FANS convenzionali nell'artrosi. <i>Pharmacoeconomics Italian Research Articles</i> , 2001 , 3, 81-89		2
12	Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions. <i>International Journal of Technology Assessment in Health Care</i> , 2020 , 36, 560-568	1.8	2
11	Cost-effectiveness of direct acting oral anticoagulants in the prevention of thromboembolic complications: limits and concerns of economic evaluations. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 500-503	1.9	2
10	Drug Prices and Value of Oncology Drugs in Italy. <i>Value in Health</i> , 2021 , 24, 1273-1278	3.3	2
9	Bayesian cost-effectiveness analysis based on the persistence with antihypertensive treatment. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2003 , 3, 227-36	2.2	1
8	A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis. <i>Leukemia and Lymphoma</i> , 2021 , 1-7	1.9	1

7	Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey. <i>Health Policy</i> , 2021 , 125, 1140-1145	3.2	1
6	Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. <i>Viruses</i> , 2022 , 14, 1197	6.2	1
5	Cyclic estrogen-progestin hormone therapy as a new therapeutic approach in the treatment of functional alterations of the hypothalamus-pituitary-ovary axis: case reports. <i>Endocrine Research</i> , 2002 , 28, 155-60	1.9	0
4	How reliable are ICER results published in current pharmacoeconomic literature? The controversial issue of price confidentiality. <i>Global & Regional Health Technology Assessment</i> , 9, 31-35	0.2	0
3	Un modello di analisi del valore dell'informazione per la valutazione di costo-efficacia nell'ambito del processo regolatorio. <i>Pharmacoeconomics Italian Research Articles</i> , 2010 , 12, 5-16		
2	Frequency of cardiovascular events in patients treated with anti hypertensive agents: A cohort study based on claims data generated by primary care practice. <i>Current Therapeutic Research</i> , 2004 , 65, 398-412	2.4	
1	Analisi costo-efficacia di due combinazioni sequenziali di trattamenti di eradicazione dell' <i>Helicobacter pylori</i> . <i>Pharmacoeconomics Italian Research Articles</i> , 2001 , 3, 15-25		